Fig. 2

Cumulative incidence of composite disease progression events for nirmatrelvir-ritonavir group vs azvudine group. A Cumulative incidence of composite disease progression (new incidents of invasive mechanical ventilation or death during 28 days of follow-up) in the nirmatrelvir-ritonavir and azvudine groups. B Landmark analysis discriminating between composite disease progression events occurring before and after 10 days of follow-up